136 related articles for article (PubMed ID: 24513025)
1. Dissociable and common effects of methylphenidate, atomoxetine and citalopram on response inhibition neural networks.
Nandam LS; Hester R; Bellgrove MA
Neuropsychologia; 2014 Apr; 56():263-70. PubMed ID: 24513025
[TBL] [Abstract][Full Text] [Related]
2. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effects of Methylphenidate, Modafinil, and MDMA on Response Inhibition Neural Networks in Healthy Subjects.
Schmidt A; Müller F; Dolder PC; Schmid Y; Zanchi D; Liechti ME; Borgwardt S
Int J Neuropsychopharmacol; 2017 Sep; 20(9):712-720. PubMed ID: 28525569
[TBL] [Abstract][Full Text] [Related]
4. Neurochemical enhancement of conscious error awareness.
Hester R; Nandam LS; O'Connell RG; Wagner J; Strudwick M; Nathan PJ; Mattingley JB; Bellgrove MA
J Neurosci; 2012 Feb; 32(8):2619-27. PubMed ID: 22357846
[TBL] [Abstract][Full Text] [Related]
5. Methylphenidate effects on prefrontal functioning during attentional-capture and response inhibition.
Pauls AM; O'Daly OG; Rubia K; Riedel WJ; Williams SC; Mehta MA
Biol Psychiatry; 2012 Jul; 72(2):142-9. PubMed ID: 22552046
[TBL] [Abstract][Full Text] [Related]
6. Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination.
Smith A; Cubillo A; Barrett N; Giampietro V; Simmons A; Brammer M; Rubia K
Biol Psychiatry; 2013 Oct; 74(8):615-22. PubMed ID: 23731741
[TBL] [Abstract][Full Text] [Related]
7. Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents.
Kowalczyk OS; Cubillo AI; Smith A; Barrett N; Giampietro V; Brammer M; Simmons A; Rubia K
Eur Neuropsychopharmacol; 2019 Oct; 29(10):1102-1116. PubMed ID: 31358436
[TBL] [Abstract][Full Text] [Related]
8. Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory.
Cubillo A; Smith AB; Barrett N; Giampietro V; Brammer M; Simmons A; Rubia K
Psychol Med; 2014 Feb; 44(3):633-46. PubMed ID: 23597077
[TBL] [Abstract][Full Text] [Related]
9. Acute caffeine administration impact on working memory-related brain activation and functional connectivity in the elderly: a BOLD and perfusion MRI study.
Haller S; Rodriguez C; Moser D; Toma S; Hofmeister J; Sinanaj I; Van De Ville D; Giannakopoulos P; Lovblad KO
Neuroscience; 2013 Oct; 250():364-71. PubMed ID: 23876323
[TBL] [Abstract][Full Text] [Related]
10. Neural correlates of error monitoring modulated by atomoxetine in healthy volunteers.
Graf H; Abler B; Freudenmann R; Beschoner P; Schaeffeler E; Spitzer M; Schwab M; Grön G
Biol Psychiatry; 2011 May; 69(9):890-7. PubMed ID: 21168122
[TBL] [Abstract][Full Text] [Related]
11. Anything goes? Regulation of the neural processes underlying response inhibition in TBI patients.
Moreno-López L; Manktelow AE; Sahakian BJ; Menon DK; Stamatakis EA
Eur Neuropsychopharmacol; 2017 Feb; 27(2):159-169. PubMed ID: 28012706
[TBL] [Abstract][Full Text] [Related]
12. The key locus of common response inhibition network for no-go and stop signals.
Zheng D; Oka T; Bokura H; Yamaguchi S
J Cogn Neurosci; 2008 Aug; 20(8):1434-42. PubMed ID: 18303978
[TBL] [Abstract][Full Text] [Related]
13. Effects of nicotine and atomoxetine on brain function during response inhibition.
Kasparbauer AM; Petrovsky N; Schmidt PM; Trautner P; Weber B; Sträter B; Ettinger U
Eur Neuropsychopharmacol; 2019 Dec; 29(2):235-246. PubMed ID: 30552041
[TBL] [Abstract][Full Text] [Related]
14. Methylphenidate effects on neural activity during response inhibition in healthy humans.
Costa A; Riedel M; Pogarell O; Menzel-Zelnitschek F; Schwarz M; Reiser M; Möller HJ; Rubia K; Meindl T; Ettinger U
Cereb Cortex; 2013 May; 23(5):1179-89. PubMed ID: 22581848
[TBL] [Abstract][Full Text] [Related]
15. Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability.
Nandam LS; Hester R; Wagner J; Cummins TD; Garner K; Dean AJ; Kim BN; Nathan PJ; Mattingley JB; Bellgrove MA
Biol Psychiatry; 2011 May; 69(9):902-4. PubMed ID: 21193172
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic modulation of brain systems subserving decision making under uncertainty: a study with fMRI and methylphenidate challenge.
Schlösser RG; Nenadic I; Wagner G; Zysset S; Koch K; Sauer H
Synapse; 2009 May; 63(5):429-42. PubMed ID: 19184997
[TBL] [Abstract][Full Text] [Related]
17. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study.
Windischberger C; Lanzenberger R; Holik A; Spindelegger C; Stein P; Moser U; Gerstl F; Fink M; Moser E; Kasper S
Neuroimage; 2010 Jan; 49(2):1161-70. PubMed ID: 19833214
[TBL] [Abstract][Full Text] [Related]
18. Manipulating brain connectivity with δ⁹-tetrahydrocannabinol: a pharmacological resting state FMRI study.
Klumpers LE; Cole DM; Khalili-Mahani N; Soeter RP; Te Beek ET; Rombouts SA; van Gerven JM
Neuroimage; 2012 Nov; 63(3):1701-11. PubMed ID: 22885247
[TBL] [Abstract][Full Text] [Related]
19. Monoaminergic modulation of behavioural and electrophysiological indices of error processing.
Barnes JJ; O'Connell RG; Nandam LS; Dean AJ; Bellgrove MA
Psychopharmacology (Berl); 2014 Jan; 231(2):379-92. PubMed ID: 23995299
[TBL] [Abstract][Full Text] [Related]
20. Functional MRI study of response inhibition in myoclonus dystonia.
van der Salm SM; van der Meer JN; Nederveen AJ; Veltman DJ; van Rootselaar AF; Tijssen MA
Exp Neurol; 2013 Sep; 247():623-9. PubMed ID: 23474191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
